Evidence map›Paper›PMID 23194305›Full record

ArticleBritish journal of pharmacology2013

Tolerance to nitroglycerin through proteasomal down-regulation of aldehyde dehydrogenase-2 in a genetic mouse model of ascorbate deficiency.

G Wölkart, M Beretta, M V Wenzl, H Stessel, K Schmidt, N Maeda, B Mayer, A Schrammel

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Ascorbate Is a Primary Antioxidant in Mammals.Molecules (Basel, Switzerland) · 2022
    Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

G WölkartDepartment of Pharmacology and Toxicology, Karl-Franzens-Universität Graz, Graz, Austria.
M Beretta
M V Wenzl
H Stessel
K Schmidt
N Maeda
B Mayer
A Schrammel
University of Graz · ATUniversity of North Carolina at Chapel Hill · US

Funding

APOLIPOROTEIN GENES AND ATHEROGENESISR01HL042630 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MAEDA, NOBUYO · 1989 to 2017
$4.9M
APOLIPOPROTEIN GENES AND ATHEROGENESIS IN ANIMALSR37HL042630 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MAEDA, NOBUYO · 1998 to 2007
$3.4M
NHLBI NIH HHS HL42630NHLBI NIH HHS R01 HL042630NHLBI NIH HHS R37 HL042630
6 · The paper itself

Abstract

background and purposeL-gulonolactone oxidase-deficient (Gulo((-/-))) mice were used to study the effects of ascorbate deficiency on aortic relaxation by nitroglycerin (GTN) with focus on changes in the expression and activity of vascular aldehyde dehydrogenase-2 (ALDH2), which catalyses GTN bioactivation. EXPERIMENTAL APPROACH: Ascorbate deficiency was induced in Gulo((-/-)) mice by ascorbate deprivation for 4 weeks. Some of the animals were concomitantly treated with the proteasome inhibitor bortezomib and effects compared with ascorbate-supplemented Gulo((-/-)), untreated or nitrate-tolerant wild-type mice. Aortic relaxation of the experimental groups to GTN, ACh and a NO donor was studied. Changes in mRNA and protein expression of vascular ALDH2 were quantified by qPCR and immunoblotting, respectively, and aortic GTN denitration rates determined. KEY

resultsLike GTN treatment, ascorbate deprivation induced vascular tolerance to GTN that was associated with markedly decreased rates of GTN denitration. Ascorbate deficiency did not affect ALDH2 mRNA levels, but reduced ALDH2 protein expression and the total amount of ubiquitinated proteins to about 40% of wild-type controls. These effects were largely prevented by ascorbate supplementation or treating Gulo((-/-)) mice with the 26S proteasome inhibitor bortezomib. CONCLUSIONS AND IMPLICATIONS: Our data indicate that ascorbate deficiency results in vascular tolerance to GTN via proteasomal degradation of ALDH2. The results support the view that impaired ALDH2-catalysed metabolism of GTN contributes significantly to the development of vascular nitrate tolerance and reveal a hitherto unrecognized protective effect of ascorbate in the vasculature.

Indexed as

Drug ToleranceModels, AnimalAldehyde DehydrogenaseAldehyde Dehydrogenase, MitochondrialAnimalsAortaAscorbic Acid DeficiencyBoronic AcidsBortezomibFemaleGene Expression Regulation, EnzymologicMaleMiceMice, Inbred C57BLMice, TransgenicNitroglycerinAldehyde DehydrogenaseAldehyde Dehydrogenase, MitochondrialALDH2 protein, mouseBoronic AcidsBortezomibNitroglycerinProteasome Endopeptidase ComplexPyrazines

Identifiers

PMID23194305
PMCPMC3623057
OpenAlexW1531514721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.